- Home
- ICLR vs BMRN Comparison
ICLR vs BMRN Comparison
Compare ICLR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- BMRN
- Stock Information
- Founded
- ICLR 1990
- BMRN 1996
- Country
- ICLR Ireland
- BMRN United States
- Employees
- ICLR N/A
- BMRN N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ICLR Health Care
- BMRN Health Care
- Exchange
- ICLR Nasdaq
- BMRN Nasdaq
- Market Cap
- ICLR 11.6B
- BMRN 12.1B
- IPO Year
- ICLR 1998
- BMRN 1999
- Fundamental
- Price
- ICLR $150.41
- BMRN $58.00
- Analyst Decision
- ICLR Buy
- BMRN Buy
- Analyst Count
- ICLR 12
- BMRN 22
- Target Price
- ICLR $187.82
- BMRN $93.43
- AVG Volume (30 Days)
- ICLR 1.1M
- BMRN 2.1M
- Earning Date
- ICLR 07-23-2025
- BMRN 08-04-2025
- Dividend Yield
- ICLR N/A
- BMRN N/A
- EPS Growth
- ICLR 11.53
- BMRN 152.82
- EPS
- ICLR 9.19
- BMRN 2.71
- Revenue
- ICLR $8,192,621,999.00
- BMRN $2,950,227,000.00
- Revenue This Year
- ICLR N/A
- BMRN $12.23
- Revenue Next Year
- ICLR $2.10
- BMRN $9.99
- P/E Ratio
- ICLR $16.55
- BMRN $21.48
- Revenue Growth
- ICLR N/A
- BMRN 19.36
- 52 Week Low
- ICLR $125.10
- BMRN $52.93
- 52 Week High
- ICLR $347.72
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- ICLR 57.67
- BMRN 59.75
- Support Level
- ICLR $146.56
- BMRN $56.76
- Resistance Level
- ICLR $155.90
- BMRN $59.98
- Average True Range (ATR)
- ICLR 4.88
- BMRN 1.44
- MACD
- ICLR 0.23
- BMRN 0.62
- Stochastic Oscillator
- ICLR 57.80
- BMRN 81.47
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.